A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Starting soon · Phase 2

Conditions studied: Breast Cancer

In brief

Objective: To explore the curative effect and safty of Changchun Ruibin metronomic chemotherapy combined with endistat in the treatment of HR positive HER2 negative advanced breast carcinoma.

Key facts

Study ID

NCT07441486

Run by

Tianjin Medical University Cancer Institute and Hospital

People needed

50

Starts

2026-04-01

Expected to finish

2026-08-30

Last updated by the study team

2026-03-02

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.